|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Narod SA, Iqbal J, Giannakeas V, Sopik V
and Sun P: Breast cancer mortality after a diagnosis of ductal
carcinoma in situ. JAMA Oncol. 1:888–896. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chung CT and Carlson RW: Goals and
objectives in the management of metastatic breast cancer.
Oncologist. 8:514–520. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Duraivelan K and Samanta D: Emerging roles
of the nectin family of cell adhesion molecules in
tumour-associated pathways. Biochim Biophys Acta Rev Cancer.
1876:1885892021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Samanta D and Almo SC: Nectin family of
cell-adhesion molecules: Structural and molecular aspects of
function and specificity. Cell Mol Life Sci. 72:645–658. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chatterjee S, Sinha S and Kundu CN: Nectin
cell adhesion molecule-4 (NECTIN-4): A potential target for cancer
therapy. Eur J Pharmacol. 15:1745162021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ooshio T, Fujita N, Yamada A, Sato T,
Kitagawa Y, Okamoto R, Nakata S, Miki A, Irie K and Takai Y:
Cooperative roles of Par-3 and afadin in the formation of adherens
and tight junctions. J Cell Sci. 120:2352–2365. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ishino R, Kawase Y, Kitawaki T, Sugimoto
N, Oku M, Uchida S, Imataki O, Matsuoka A, Taoka T, Kawakami K, et
al: Oncolytic virus therapy with HSV-1 for hematological
malignancies. Mol Ther. 29:762–774. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mühlebach MD, Mateo M, Sinn PL, Prüfer S,
Uhlig KM, Leonard VH, Navaratnarajah CK, Frenzke M, Wong XX,
Sawatsky B, et al: Adherens junction protein nectin-4 is the
epithelial receptor for measles virus. Nature. 480:530–533. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Athanassiadou AM, Patsouris E, Tsipis A,
Gonidi M and Athanassiadou P: The significance of survivin and
nectin-4 expression in the prognosis of breast carcinoma. Folia
Histochem Cytobiol. 49:26–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fabre-Lafay S, Monville F, Garrido-Urbani
S, Berruyer-Pouyet C, Ginestier C, Reymond N, Finetti P, Sauvan R,
Adélaïde J, Geneix J, et al: Nectin-4 is a new histological and
serological tumour associated marker for breast cancer. BMC Cancer.
7:732007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takano A, Ishikawa N, Nishino R, Masuda K,
Yasui W, Inai K, Nishimura H, Ito H, Nakayama H, Miyagi Y, et al:
Identification of nectin-4 oncoprotein as a diagnostic and
therapeutic target for lung cancer. Cancer Res. 69:6694–6703. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Derycke MS, Pambuccian SE, Gilks CB,
Kalloger SE, Ghidouche A, Lopez M, Bliss RL, Geller MA, Argenta PA,
Harrington KM and Skubitz AP: Nectin 4 overexpression in ovarian
cancer tissues and serum: Potential role as a serum biomarker. Am J
Clin Pathol. 134:835–845. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pavlova NN, Pallasch C, Elia AE, Braun CJ,
Westbrook TF, Hemann M and Elledge SJ: A role for PVRL4-driven
cell-cell interactions in tumorigenesis. Elife. 30:e003582013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Siddharth S, Goutam K, Das S, Nayak A,
Nayak D, Sethy C, Wyatt MD and Kundu CN: Nectin-4 is a breast
cancer stem cell marker that induces WNT/β-catenin signaling via
Pi3k/Akt axis. Int J Biochem Cell Biol. 89:85–94. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Deng H, Shi H, Chen L, Zhou Y and Jiang J:
Over-expression of Nectin-4 promotes progression of esophageal
cancer and correlates with poor prognosis of the patients. Cancer
Cell Int. 19:1062019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bellmunt J, Kim J, Reardon B, Perera-Bel
J, Orsola A, Rodriguez-Vida A, Wankowicz SA, Bowden M, Barletta JA,
Morote J, et al: Genomic predictors of good outcome, recurrence, or
progression in high-grade T1 non-muscle-invasive bladder cancer.
Cancer Res. 80:4476–4486. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bouleftour W, Guillot A and Magne N: The
anti-nectin 4: A promising tumor cells target. A systematic review.
Mol Cancer Ther. 21:493–501. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
M-Rabet M, Cabaud O, Josselin E, Finetti
P, Castellano R, Farina A, Agavnian-Couquiaud E, Saviane G,
Collette Y, Viens P, et al: Nectin-4: A new prognostic biomarker
for efficient therapeutic targeting of primary and metastatic
triple-negative breast cancer. Ann Oncol. 28:769–776. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sugiyama T, Yoneda M, Kuraishi T, Hattori
S, Inoue Y, Sato H and Kai C: Measles virus selectively blind to
signaling lymphocyte activation molecule as a novel oncolytic virus
for breast cancer treatment. Gene Ther. 20:338–347. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Challita-Eid PM, Satpayev D, Yang P, An Z,
Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR, et
al: Enfortumab vedotin antibody-drug conjugate targeting nectin-4
is a highly potent therapeutic agent in multiple preclinical cancer
models. Cancer Res. 76:3003–3013. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hagège H, Klous P, Braem C, Splinter E,
Dekker J, Cathala G, de Laat W and Forné T: Quantitative analysis
of chromosome conformation capture assays (3C-qPCR). Nat Protoc.
2:1722–1733. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schilit SLP and Morton CC: 3C-PCR: A novel
proximity ligation-based approach to phase chromosomal
rearrangement breakpoints with distal allelic variants. Hum Genet.
137:55–62. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yamaguchi K, Yamaguchi R, Takahashi N,
Ikenoue T, Fujii T, Shinozaki M, Tsurita G, Hata K, Niida A, Imoto
S, et al: Overexpression of cohesion establishment factor DSCC1
through E2F in colorectal cancer. PLoS One. 9:e857502014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou Y, Zhou B, Pache L, Chang M,
Khodabakhshi AH, Tanaseichuk O, Benner C and Chanda SK: Metascape
provides a biologist-oriented resource for the analysis of
systems-level datasets. Nat Commun. 10:15232019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kharman-Biz A, Gao H, Ghiasvand R, Zhao C,
Zendehdel K and Dahlman-Wright K: Expression of activator protein-1
(AP-1) family members in breast cancer. BMC Cancer. 13:4412013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Szalóki N, Krieger JW, Komáromi I, Tóth K
and Vámosi G: Evidence for homodimerization of the c-Fos
transcription factor in live cells revealed by fluorescence
microscopy and computer modeling. Mol Cell Biol. 35:3785–3798.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Young DF, Andrejeva J, Li X,
Inesta-Vaquera F, Dong C, Cowling VH, Goodbourn S and Randall RE:
Human IFIT1 inhibits mRNA translation of rubulaviruses but not
other members of the paramyxoviridae family. J Virol. 90:9446–9456.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Busse DC, Habgood-Coote D, Clare S, Brandt
C, Bassano I, Kaforou M, Herberg J, Levin M, Eléouët JF, Kellam P
and Tregoning JS: Interferon-induced protein 44 and
interferon-induced protein 44-like restrict replication of
respiratory syncytial virus. J Virol. 94:e00297–e00320. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Han Y, Bai X, Liu S, Zhu J, Zhang F, Xie
L, Liu G, Jiang X, Zhang M, Huang Y, et al: XAF1 protects host
against emerging RNA viruses by stabilizing IRF1-dependent
antiviral immunity. J Virol. 96:e00774222022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Haller O and Kochs G: Mx genes: Host
determinants controlling influenza virus infection and
trans-species transmission. Hum Genet. 139:695–705. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kuang M, Zhao Y, Yu H, Li S, Liu T, Chen
L, Chen J, Luo Y, Guo X, Wei X, et al: XAF1 promotes anti-RNA virus
immune responses by regulating chromatin accessibility. Sci Adv.
9:eadg52112023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liao X, Xie H, Li S, Ye H, Li S, Ren K, Li
Y, Xu M, Lin W, Duan X, et al: 2′, 5′-oligoadenylate synthetase 2
(OAS2) inhibits zika virus replication through activation of type I
IFN signaling pathway. Viruses. 12:4182020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Duan R, Porter W and Safe S:
Estrogen-induced c-fos protooncogene expression in MCF-7 human
breast cancer cells: Role of estrogen receptor Sp1 complex
formation. Endocrinology. 139:1981–1990. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Binato R, Corrêa S, Panis C, Ferreira G,
Petrone I, da Costa IR and Abdelhay E: NRIP1 is activated by
C-JUN/C-FOS and activates the expression of PGR, ESR1 and CCND1 in
luminal A breast cancer. Sci Rep. 11:211592021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kawahara T, Shareef HK, Aljarah AK, Ide H,
Li Y, Kashiwagi E, Netto GJ, Zheng Y and Miyamoto H: ELK1 is
up-regulated by androgen in bladder cancer cells and promotes tumor
progression. Oncotarget. 6:29860–29876. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhou H, Zarubin T, Ji Z, Min Z, Zhu W,
Downey JS, Lin S and Han J: Frequency and distribution of AP-1
sites in the human genome. DNA Res. 12:139–150. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Roskoski R Jr: ERK1/2 MAP kinases:
Structure, function, and regulation. Pharmacol Res. 66:105–143.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bakiri L, Reschke MO, Gefroh HA, Idarraga
MH, Polzer K, Zenz R, Schett G and Wagner EF: Functions of Fos
phosphorylation in bone homeostasis, cytokine response and
tumourigenesis. Oncogene. 31:1506–1517. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang L, Yang M, Guo X, Yang Z, Liu S, Ji Y
and Jin H: Estrogen-related receptor-α promotes gallbladder cancer
development by enhancing the transcription of nectin-4. Cancer Sci.
111:1514–1527. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Reches A, Ophir Y, Stein N, Kol I,
Isaacson B, Charpak Amikam Y, Elnekave A, Tsukerman P, Kucan Brlic
P, Lenac T, et al: Nectin4 is a novel TIGIT ligand which combines
checkpoint inhibition and tumor specificity. J Immunother Cancer.
8:e0002662020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Maruoka M, Kedashiro S, Ueda Y, Mizutani K
and Takai Y: Nectin-4 co-stimulates the prolactin receptor by
interacting with SOCS1 and inhibiting its activity on the
JAK2-STAT5a signaling pathway. J Biol Chem. 292:6895–6909. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liau NPD, Laktyushin A, Lucet IS, Murphy
JM, Yao S, Whitlock E, Callaghan K, Nicola NA, Kershaw NJ and Babon
JJ: The molecular basis of JAK/STAT inhibition by SOCS1. Nat
Commun. 9:15582018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fulco CP, Munschauer M, Anyoha R, Munson
G, Grossman SR, Perez EM, Kane M, Cleary B, Lander ES and Engreitz
JM: Systematic mapping of functional enhancer-promoter connections
with CRISPR interference. Science. 354:769–773. 2016. View Article : Google Scholar : PubMed/NCBI
|
